[go: up one dir, main page]

SE9301667D0 - New use - Google Patents

New use

Info

Publication number
SE9301667D0
SE9301667D0 SE19939301667A SE9301667A SE9301667D0 SE 9301667 D0 SE9301667 D0 SE 9301667D0 SE 19939301667 A SE19939301667 A SE 19939301667A SE 9301667 A SE9301667 A SE 9301667A SE 9301667 D0 SE9301667 D0 SE 9301667D0
Authority
SE
Sweden
Prior art keywords
nmda
receptor
new use
glutamate
glutamate receptors
Prior art date
Application number
SE19939301667A
Other languages
English (en)
Swedish (sv)
Inventor
P *Bourguignon J
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE19939301667A priority Critical patent/SE9301667D0/xx
Publication of SE9301667D0 publication Critical patent/SE9301667D0/xx
Priority to DK94916460T priority patent/DK0697886T3/da
Priority to ES94916460T priority patent/ES2204916T3/es
Priority to AT94916460T priority patent/ATE247481T1/de
Priority to CA002162924A priority patent/CA2162924C/fr
Priority to PCT/SE1994/000454 priority patent/WO1994026301A1/fr
Priority to AU68108/94A priority patent/AU685123B2/en
Priority to JP52470594A priority patent/JP3819932B2/ja
Priority to NZ266559A priority patent/NZ266559A/xx
Priority to EP94916460A priority patent/EP0697886B1/fr
Priority to DE69433058T priority patent/DE69433058T2/de
Priority to US08/549,798 priority patent/US5804550A/en
Priority to US10/087,011 priority patent/US20020115594A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE19939301667A 1993-05-14 1993-05-14 New use SE9301667D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE19939301667A SE9301667D0 (sv) 1993-05-14 1993-05-14 New use
DE69433058T DE69433058T2 (de) 1993-05-14 1994-05-16 Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren
CA002162924A CA2162924C (fr) 1993-05-14 1994-05-16 Nouveaux antagonistes a base de peptides pour les recepteurs de ndma et de glutamate
ES94916460T ES2204916T3 (es) 1993-05-14 1994-05-16 Nuevos antagonistas peptidos de los receptores de glutamato y nmda.
AT94916460T ATE247481T1 (de) 1993-05-14 1994-05-16 Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren
DK94916460T DK0697886T3 (da) 1993-05-14 1994-05-16 Nye peptidantagonister for glutamat- og NMDA-receptorer
PCT/SE1994/000454 WO1994026301A1 (fr) 1993-05-14 1994-05-16 Nouveaux antagonistes peptidiques de recepteurs du glutamate et du nmda
AU68108/94A AU685123B2 (en) 1993-05-14 1994-05-16 New peptide antagonists at glutamate and NMDA receptors
JP52470594A JP3819932B2 (ja) 1993-05-14 1994-05-16 グルタミン酸塩およびｎｍｄａレセプターにおけるペプチド拮抗物質の使用方法
NZ266559A NZ266559A (en) 1993-05-14 1994-05-16 Peptide antagonists of cellular glutamate or NMDA receptors
EP94916460A EP0697886B1 (fr) 1993-05-14 1994-05-16 Nouveaux antagonistes peptidiques de recepteurs du glutamate et du nmda
US08/549,798 US5804550A (en) 1993-05-14 1995-11-09 Peptide antagonists at glutamate and NMDA receptors
US10/087,011 US20020115594A1 (en) 1993-05-14 2002-02-26 Peptide antagonists at glutamate and NMDA receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301667A SE9301667D0 (sv) 1993-05-14 1993-05-14 New use

Publications (1)

Publication Number Publication Date
SE9301667D0 true SE9301667D0 (sv) 1993-05-14

Family

ID=20389945

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939301667A SE9301667D0 (sv) 1993-05-14 1993-05-14 New use

Country Status (12)

Country Link
US (2) US5804550A (fr)
EP (1) EP0697886B1 (fr)
JP (1) JP3819932B2 (fr)
AT (1) ATE247481T1 (fr)
AU (1) AU685123B2 (fr)
CA (1) CA2162924C (fr)
DE (1) DE69433058T2 (fr)
DK (1) DK0697886T3 (fr)
ES (1) ES2204916T3 (fr)
NZ (1) NZ266559A (fr)
SE (1) SE9301667D0 (fr)
WO (1) WO1994026301A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812208B2 (en) * 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
EP0735894A4 (fr) * 1993-12-23 1999-08-18 Auckland Uniservices Ltd Composition et procedes permettant d'ameliorer l'issue d'etats pathologiques du systeme nerveux
GB9611584D0 (en) * 1996-06-04 1996-08-07 Univ Edinburgh Neurotransmitters
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
ES2325983T3 (es) 2001-05-24 2009-09-28 Neuren Pharmaceuticals Limited Analogos y peptidomimeticos de gpe.
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
AU2003218460A1 (en) * 2002-04-05 2003-10-27 Neuronz Biosciences, Inc. Compositions and methods for immunomodulation
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh
EP1529533A1 (fr) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Utilisation de sécrétagogues de l'hormone de croissance dans le traitement des lésions cérébrales ischémiques et hypoxiques
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG183265A1 (en) 2010-02-11 2012-09-27 Univ Northwestern Secondary structure stabilized nmda receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2898863A1 (fr) 2013-01-29 2014-08-07 Naurex, Inc. Modulateurs spirolactames d'un recepteur nmda et leurs utilisations
ES2618421T3 (es) 2013-01-29 2017-06-21 Aptinyx Inc. Moduladores espiro-lactama del receptor NMDA y usos de los mismos
MX375286B (es) 2013-01-29 2025-03-06 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
CN105229011B (zh) 2013-01-29 2018-02-06 阿普廷伊克斯股份有限公司 螺‑内酰胺nmda受体调节剂及其用途
PE20151438A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
CA3024606C (fr) 2016-05-19 2019-09-03 Aptinyx Inc. Modulateurs de recepteurs nmda de spiro-lactame et utilisations associees
WO2017201285A1 (fr) 2016-05-19 2017-11-23 Aptinyx Inc. Modulateurs spirolactames des récepteurs nmda et leurs utilisations
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
WO2018026782A1 (fr) 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs spirolactames des récepteurs nmda et leurs utilisations
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017557A (en) * 1987-07-24 1991-05-21 Industria Farmaceutica Serono S.P.A. Treatment of infertility with somatotrophin releasing factor
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
DK0597033T3 (da) * 1991-08-01 1997-06-02 Genentech Inc IGF-1 til forbedring af den neurale tilstand

Also Published As

Publication number Publication date
US20020115594A1 (en) 2002-08-22
CA2162924A1 (fr) 1994-11-24
NZ266559A (en) 2000-12-22
DE69433058D1 (de) 2003-09-25
JP3819932B2 (ja) 2006-09-13
ES2204916T3 (es) 2004-05-01
EP0697886B1 (fr) 2003-08-20
DK0697886T3 (da) 2003-10-20
US5804550A (en) 1998-09-08
EP0697886A1 (fr) 1996-02-28
AU6810894A (en) 1994-12-12
WO1994026301A1 (fr) 1994-11-24
JPH08510214A (ja) 1996-10-29
DE69433058T2 (de) 2004-06-03
ATE247481T1 (de) 2003-09-15
CA2162924C (fr) 2008-12-30
AU685123B2 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
SE9301667D0 (sv) New use
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
ID28003A (id) Turunan-turunan adamantana
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
NO951613L (no) Ikke-peptidyl tachykinin reseptorantagonister
DE59601122D1 (de) N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
DK0817847T4 (da) IL-17-receptor
DK1036058T3 (da) Adamantanderivater
EA199800376A1 (ru) Антагонисты рецепторов возбудительной аминокислоты
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
ATE87918T1 (de) Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
NO953892D0 (no) Imidazolokinoksalinon-derivater som EAA-antagonister
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
SE9304236D0 (sv) New use
ATE240097T1 (de) Pharmaceutische zusammensetzung enthaltend (+)- ephedrin und einen h1 rezeptor antagonisten